TBXT and chordoma: In summary, our data indicate that chordoma cells require JAK-STAT signaling driven by TBXT, particularly JAK2, suggesting an immediately applicable strategy for targeted treatment of patients with chordoma using clinically approved JAK2 inhibitors.